Literature DB >> 6259058

Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.

O A Carretero, S Miyazaki, A G Scicli.   

Abstract

The role of kinins in the acute antihypertensive effect of a converting enzyme inhibitor (CEI) was studied in sodium-depleted normotensive and in two-kidney, one clip chronically hypertensive rats (2K-1C). The 2K-1C were on a normal sodium diet. The acute vasodepressor effect of the CEI was determined in these two groups either after administration of normal rabbit globulins or antikinin globulins. The amount of kinin antibodies administered completely blocked the hypotensive effects of bradykinin, 400 ng/kg, and urinary kallikrein, 4 microgram/kg. After administration of CEI in the sodium-depleted rats there was no significant difference (p greater than 0.05) in the acute changes in mean blood pressure (BP) between the group pretreated with normal rabbit globulins (delta BP -32.3 +/- 3.9 mm Hg) and the group pretreated with antikinin globulins (delta BP -25 +/- 2.5 mm Hg). In the 2K-1C pretreated with normal rabbit globulins, the CEI produced a decrease in BP of -21 +/- 4.5 mm Hg. This decrease was almost completely blocked in the group pretreated with the antikinin globulins (delta BP -4 +/- 4.1 mm Hg). These differences in the changes in BP were significant (p less than 0.02). These results suggest that the acute antihypertensive effect of the CEI in the sodium-depleted rats is probably due to inhibition of the conversion of angiotensin I to II while in the 2K-1C it is due, in part, to an increase in kinin concentrations secondary to the inhibition of kininase II.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259058     DOI: 10.1161/01.hyp.3.1.18

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

1.  Hemodynamic effects of benazepril, an angiotensin-converting enzyme inhibitor, as studied in conscious normotensive dogs.

Authors:  T Ishibashi; S Tatebe; A Mitomi; M Tanaka; S Imai
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 2.  Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.

Authors:  V J Dzau
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Angiotensin-converting enzyme inhibitors or calcium channel blockers? An overview.

Authors:  H Gavras
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors.

Authors:  G Bönner
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Kallikrein activates bradykinin B2 receptors in absence of kininogen.

Authors:  Dauren Biyashev; Fulong Tan; Zhenlong Chen; Kai Zhang; Peter A Deddish; Ervin G Erdös; Claudie Hecquet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-04       Impact factor: 4.733

6.  Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.

Authors:  S Miyazaki; K Miura; Y Kasai; K Abe; K Yoshinaga
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

7.  The role of endogenous bradykinin in blood pressure homeostasis in spontaneously hypertensive rats.

Authors:  H R Holte; A Bjørnstad-Ostensen; T Berg
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 8.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03

Review 9.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

10.  Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.

Authors:  T Sakamoto; C Chen; M F Lokhandwala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.